LOGO
LOGO

Aldeyra To Make Second Bid For FDA Approval Of Dry Eye Disease Drug

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

Dry eye disease is an ocular condition where the eyes do not produce enough tears or make the right type of tears or tear film. It is estimated that there are approximately 39 million dry eye disease patients in the United States.

The stock we are bringing to your attention today is that of Aldeyra Therapeutics Inc. (ALDX), which despite facing an initial setback in obtaining FDA approval for its investigational dry eye disease treatment last year, is set to make another attempt later this year.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.